The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron
 
Sandro Porceddu
Consulting or Advisory Role - Regeneron
Patents, Royalties, Other Intellectual Property - UPTODATE Royalties for Author of a Chapter
 
Fiona Day
Leadership - Icon Cancer Care
Consulting or Advisory Role - Regeneron
Patents, Royalties, Other Intellectual Property - UpToDate
 
Daniel Brungs
Consulting or Advisory Role - AstraZeneca; MSD
Travel, Accommodations, Expenses - MSD Oncology
 
Hayden Christie
Honoraria - Bayer
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
James Jackson
Stock and Other Ownership Interests - Icon Cancer Center
 
Brian Stein
Stock and Other Ownership Interests - Icon Cancer Center
 
Annette Lim
Research Funding - Peter MacCallum Cancer Center; Regeneron (Inst)
 
Yungpo Su
No Relationships to Disclose
 
Samantha Bowyer
Consulting or Advisory Role - Boehringer Ingelheim; Janssen Oncology; Medison; Merck Sharp & Dohme; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Medison; Merck Sharp & Dohme
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Janssen; Merck Sharp & Dohme
 
Naoya Yamazaki
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Merck; Ono Pharmaceutical; Otsuka
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); HUYA Bioscience International (Inst); MSD (Inst); Novartis (Inst); Regeneron (Inst); Takara Bio (Inst)
 
Paolo Bossi
Honoraria - BeiGene; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; LEO Pharma; Merck; Merus; MSD Oncology; Nutricia; Pfizer; Regeneron; Sun Pharma
Consulting or Advisory Role - Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck Serono; MSD Oncology; Nutricia; Sanofi/Regeneron; Sun Pharma
Research Funding - AstraZeneca (Inst); BeiGene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Merus NV (Inst); MSD Oncology (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Merck Serono
 
Armarnath Challapalli
Consulting or Advisory Role - Merck; Regeneron; Sanofi
Research Funding - Regeneron (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen
 
Rahul Ladwa
Honoraria - MSD (Inst); Sanofi (Inst)
Consulting or Advisory Role - La Roche-Posay (Inst); Merck Sharp & Dohme (Inst)
Research Funding - MSD
Travel, Accommodations, Expenses - MSD; Sanofi
 
Axel Hauschild
Honoraria - Agenus; Almirall Hermal GmbH; Bristol-Myers Squibb; CureVac; Immunocore; Incyte; IO Biotech; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Regeneron; Replimune; Roche; Sanofi/Aventis; Skyline Diagnostics; Sun Pharma; Xenthera
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Debra McIntyre
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Frank Seebach
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Suk-Young Yoo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Priscila Goncalves
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - I am an inventor on 2 patents, as a REGENERON employee - PCT publication 2023/133280 - PCT publication 2023/17772
 
Matthew Fury
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron